Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience

The use of immune checkpoint inhibition (ICI) has revolutionized cancer treatment. However, these medications are associated with significant and potentially debilitating immune-related adverse events (irAEs). While certain toxicities have been well studied, rheumatic complications have been less widely recognized and characterized. We report our experience of patients who were evaluated by rheumatology after the development of a suspected...